Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice

Clinical Therapeutics

Volumn 21, Issue 6, 1999, Pages 1074-1090

  Farmer, Kevin C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Adherence; Compliance; Measurement; Medication use; Monitoring device

Indexed keywords

DRUG;

AMBULATORY MONITORING; CLINICAL PRACTICE; CLINICAL TRIAL; DEVICE; DRUG MONITORING; DRUG USE; HUMAN; META ANALYSIS; METHODOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; QUESTIONNAIRE; REVIEW; SELF REPORT;

EID: 0032796185     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80026-5     Document Type: Article

References (61)

1. 1. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979.
2. 2. Haynes RB, Wang E, Da Mota Gomes M. A critical review of interventions to improve compliance with prescribed medications. Patient Educ Couns. 1987;10:155-166.
3. 3. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-386.
4. 4. Greenberg RN. Overview of patient compliance with medication dosing: A literature review. Clin Ther. 1984;6:592-599.
5. 5. Rogers PG, Bullman WR. Prescription medicine compliance: A review of the baseline of knowledge. Washington, DC: National Council on Patient Information and Education; 1995:1-42.
6. 6. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32:749-754.
7. 7. Wright EC. Non-compliance - or how many aunts has Matilda? Lancet. 1993; 342:909-913.
8. 8. Hurley FL. Statistical approach to subgroup analyses: Patient compliance data and clinical outcomes. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991:243-250.
9. 9. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. 1993;270:742-744.
10. 10. Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991:265-282.
11. 11. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991:195-207.
12. 12. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? NEJM. 1995;332:1125-1131.
13. 13. Gibaldi M. Compliance in clinical trials. Pharmaceutical News. 1996;3:16-18.
14. 14. Brittain E, Wittes J. The run-in period in clinical trials: The effect of misclassification on efficiency. Control Clin Trials. 1990;11:327-338.
15. 15. Cramer JA, Maltson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991: 123-137.
16. 16. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. NEJM. 1978; 299:926-930.
17. 17. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2:757-764.
18. 18. Matsui D, Hermann C, Klein JJ, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34:944-949.
19. 19. Craig HM. Accuracy of indirect measures of medication compliance in hypertension. Res Nurs Health. 1985;8:61-66.
20. 20. Pullar T, Feely MP. Reporting compliance in clinical trials. Lancet. 1990;336:1252-1253. Letter.
21. 21. Pullar T, Kumar S, Tindall H, Feely MP. Time to stop counting the tablets? Clin Pharmacol Ther. 1989;46:163-168.
22. 22. Gregoire J-P, Guilbert R, Archambault A, Contandriopoulos A-P. Measurement of non-compliance to antihypertensive medication using pill counts and pharmacy records. J Soc Adm Pharm. 1998;14:198-207.
23. 23. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150:1377-1378.
24. 24. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509-1510.
25. 25. Dirks JF, Kinsman R. Nondichotomous patterns of medication usage: The yes-no fallacy. Clin Pharmacol Ther. 1982;31:413-417.
26. 26. Straka RJ, Fish JT, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: An evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy. 1997;17:126-132.
27. 27. Park LC, Lipman RS. A comparison of patient dosage deviation reports with pill counts. Psychopharmacologia. 1964;6:299-302.
28. 28. Inui TS, Carter WB, Pecoraro RE. Screening for noncompliance among patients with hypertension: Is self-report the best available measure? Med Care. 1981;19:1061-1064.
29. 29. Gordis L, Markowitz M, Lilienfeld AM. The inaccuracy in using interviews to estimate patient reliability in taking medications at home. Med Care. 1969;7:49-54.
30. 30. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
31. 31. Myers ED, Branthwaite A. Out-patient compliance with antidepressant medication. Br J Psychiatry. 1992;160:83-86.
32. 32. Roter DL, Hall JA. Studies of doctor-patient interaction. Ann Rev Public Health. 1989;10:163-180.
33. 33. Davis M. Variations in patients' compliance with doctors' advice: An empirical analysis of patterns of communication. Am J Public Health. 1969;58:274-288.
34. 34. Ross FM. Patient compliance - whose responsibility? Soc Sci Med. 1991;32:89-94.
35. 35. Sherbourne CD, Hays RD, Ordway L, et al. Antecedents of adherence to medical recommendations: Results from the Medical Outcomes Study. J Behav Med. 1992; 15:447-468.
36. 36. Stewart M. The validity of an interview to assess a patient's drug taking. Am J Prev Med. 1987;3:95-100.
37. 37. Sumartojo E. When tuberculosis treatment fails: A social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311-1320.
38. 38. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Educ Couns. In press.
39. 39. Spilker B. Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991:37-56.
40. 40. Rand CS, Wise RA, Nides MA, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 1992;146:1559-1564.
41. 41. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
42. 42. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
43. 43. Craghead RM, Wartski DM, An evaluative study of unclaimed prescriptions. Hosp Pharm . 1991;26:616-617.
44. 44. Craghead RM, Wartski DM. Effect of automated prescription transmittal on number of unclaimed prescriptions. Am J Hosp Pharm. 1989;46:310-312.
45. 45. Steiner JF, Kocpsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Med Care. 1988;26:814-823.
46. 46. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm. 1992;49: 1691-1696.
47. 47. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: Adherence by the elderly. Am J Public Health. 1993;83:711-716.
48. 48. Christensen DB, Williams B, Goldberg HI, et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care. 1997;35:1164-1170.
49. 49. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther. 1994;16:316-326.
50. 50. Sclar DA, Skaer TL, Okamoto MP, Gill MA. Effectiveness of the C Cap in promoting prescription refill compliance among patients with glaucoma. Clin Ther. 1991;13:396-400.
51. 51. Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens. 1993;7:515-518.
52. 52. Farris KB, Kaplan B, Kirking DM. Examination of days supply in computerized prescription claims. J Pharmacoepidemiol. 1994;3:63-76.
53. 53. Burney KD, Krishnan K, Ruffin MT, et al. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Arch Fam Med. 1996;5:297-300.
54. 54. Elixhauser A, Eisen SA, Romeis JC, Homan SM. The effects of monitoring and feedback on compliance. Med Care. 1990; 28:882-893.
55. 55. Kastrissios H, Flowers NT, Blaschke TF. Introducing medical students to medication noncompliance. Clin Pharmacol Ther. 1996;59:577-582.
56. 56. Halpern MT, Irwin DE, Brown RE, et al. Patient adherence to prescribed potassium supplement therapy. Clin Ther. 1993;15: 1133-1145.
57. 57. Jacobs J, Goldstein AG, Kelly ME, Bloom BS. NSAID dosing schedule and compliance. Drug Intell Clin Pharm. 1988;22: 727-728.
58. 58. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting. Comparison of three methods in patients prescribed digoxin. Arch Intern Med. 1979;139:635-638.
59. 59. Spector SL, Kinsman R, Mawhinney H, et al. Compliance of patients with asthma with an experimental aerosolized medication: Implications for controlled clinical trials. J Allergy Clin Immunol. 1986;77:65-70.
60. 60. Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med. 1979;139:627-628.
61. 61. FDA Center for Drug Evaluation and Research. Guidance for Industry: General Considerations for the Clinical Evaluation of Drugs. Federal Regulation 21 Part 312.56. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, 1997.